Search Results - "MELERO, I"

Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy by Sznol, M., Melero, I.

Get full text

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies by Sanmamed, M.F., Chester, C., Melero, I., Kohrt, H.

“…The recent success of checkpoint blockers to treat cancer has demonstrated that the immune system is a critical player in the war against cancer. Historically,…”
Get full text

Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets? by Melero, I., Normanno, N.

Get full text

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) by Marabelle, A., Andtbacka, R., Harrington, K., Melero, I., Leidner, R., de Baere, T., Robert, C., Ascierto, P.A., Baurain, J -F, Imperiale, M., Rahimian, S., Tersago, D., Klumper, E., Hendriks, M., Kumar, R., Stern, M., Öhrling, K., Massacesi, C., Tchakov, I., Tse, A., Douillard, J -Y, Tabernero, J., Haanen, J., Brody, J.

“…A European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 8 March 2018 which comprised 11 experts from academia, 11 experts…”
Get full text

Reply to the Letter to the Editor "Reflections on the statistical methodology in nivolumab and ipilimumab therapy research" by S. Yang by Melero, I, Soleymani, S, Tschaika, M, El-Khoueiry, A B

Get more information

Predictors of responses to immune checkpoint blockade in advanced melanoma by Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., Woods, D. M., Sodré, A. L., Hansen, M., Meirow, Y., Sade-Feldman, M., Burra, A., Kwek, S. S., Flament, C., Messaoudene, M., Duong, C. P. M., Chen, L., Kwon, B. S., Anderson, A. C., Kuchroo, V. K., Weide, B., Aubin, F., Borg, C., Dalle, S., Beatrix, O., Ayyoub, M., Balme, B., Tomasic, G., Di Giacomo, A. M., Maio, M., Schadendorf, D., Melero, I., Dréno, B., Khammari, A., Dummer, R., Levesque, M., Koguchi, Y., Fong, L., Lotem, M., Baniyash, M., Schmidt, H., Svane, I. M., Kroemer, G., Marabelle, A., Michiels, S., Cavalcanti, A., Smyth, M. J., Weber, J. S., Eggermont, A. M., Zitvogel, L.

“…Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune…”
Get full text

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy by Sánchez-Paulete, A R, Teijeira, A, Cueto, F J, Garasa, S, Pérez-Gracia, J L, Sánchez-Arráez, A, Sancho, D, Melero, I

“…Dendritic cells (DCs) are the main professional antigen-presenting cells for induction of T-cell adaptive responses. Cancer cells express tumor antigens,…”
Get full text

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma by Paiva, B, Azpilikueta, A, Puig, N, Ocio, E M, Sharma, R, Oyajobi, B O, Labiano, S, San-Segundo, L, Rodriguez, A, Aires-Mejia, I, Rodriguez, I, Escalante, F, de Coca, A G, Barez, A, San Miguel, J F, Melero, I

Get full text

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients by Rodríguez-Ruiz, M.E., Perez-Gracia, J.L., Rodríguez, I., Alfaro, C., Oñate, C., Pérez, G., Gil-Bazo, I., Benito, A., Inogés, S., López-Diaz de Cerio, A., Ponz-Sarvise, M., Resano, L., Berraondo, P., Barbés, B., Martin-Algarra, S., Gúrpide, A., Sanmamed, M.F., de Andrea, C., Salazar, A.M., Melero, I.

“…Combination immunotherapy has the potential to achieve additive or synergistic effects. Combined local injections of dsRNA analogues (mimicking viral RNA) and…”
Get full text

De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock by Garnacho-Montero, J., Gutiérrez-Pizarraya, A., Escoresca-Ortega, A., Corcia-Palomo, Y., Fernández-Delgado, Esperanza, Herrera-Melero, I., Ortiz-Leyba, C., Márquez-Vácaro, J. A.

“…Purposes We set out to assess the safety and the impact on in-hospital and 90-day mortality of antibiotic de-escalation in patients admitted to the ICU with…”
Get full text

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022 by Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., Stathis, A., Steeghs, N., Yap, C., Yap, T.A., Ratain, M., Seymour, L.

“…In 2021, the Food and Drug Administration Oncology Center of Excellence announced Project Optimus focusing on dose optimization for oncology drugs. The…”
Get full text

AEDV expert consensus document on the organization of a multidisciplinary unit for patients with or at risk of venereal infections by Monroig, J Riera, Feltes-Ochoa, R A, Melero, I Quiles, Gorgojo, A Martin

“…Over the past few years, venereal or sexually transmitted infections (STIs) have been on the rise worldwide requiring additional specialized monographic…”
Get full text

Cancer immunotherapy full speed ahead by Melero, I, Navarro, B, Teijeira, A, Coukos, G

Get full text

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes by Alfaro, C, Suarez, N, Gonzalez, A, Solano, S, Erro, L, Dubrot, J, Palazon, A, Hervas-Stubbs, S, Gurpide, A, Lopez-Picazo, J M, Grande-Pulido, E, Melero, I, Perez-Gracia, J L

“…Vascular endothelial growth factor (VEGF) inhibits differentiation and maturation of dendritic cells (DC), suggesting a potential immunosuppressive role for…”
Get full text

Regional and intratumoral adoptive T-cell therapy by Olivera, I., Etxeberria, I., Luri-Rey, C., Molero-Glez, P., Melero, I.

“…Adoptive T-cell therapies (ACTs) including tumor-infiltrating lymphocytes and engineered T cells (transgenic T-cell receptor and chimeric antigen receptor T…”
Get full text

Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy by Sánchez-Paulete, A R, Teijeira, A, Cueto, F J, Garasa, S, Pérez-Gracia, J L, Sánchez-Arráez, A, Sancho, D, Melero, I

Get full text

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040 by Melero, I, Yau, T, Kang, Y-K, Kim, T-Y, Santoro, A, Sangro, B, Kudo, M, Hou, M-M, Matilla, A, Tovoli, F, Knox, J, He, A R, El-Rayes, B, Acosta-Rivera, M, Lim, H Y, Soleymani, S, Yao, J, Neely, J, Tschaika, M, Hsu, C, El-Khoueiry, A B

“…Nivolumab plus ipilimumab demonstrated promising clinical activity and durable responses in sorafenib-treated patients with advanced hepatocellular carcinoma…”
Get more information

[Translated article] AEDV Expert Consensus Document on the Organization of a Multidisciplinary Unit for Patients With or at Risk of Venereal Infections by Riera-Monroig, J., Feltes-Ochoa, R.A., Quiles-Melero, I., Martin-Gorgojo, A.

“…Over the past few years, venereal or sexually transmitted infections (STIs) have been on the rise worldwide requiring additional specialized monographic…”
Get full text

Descriptive study of spinal instrumentation-related infections in a tertiary hospital by Rico Nieto, A, Loeches Yagüe, B, Quiles Melero, I, Talavera Buedo, G, Pizones, J, Fernández-Baillo Sacristana, N

“…Spinal instrumentation-related infections (SIRI) are one of the main causes of post-surgical complication and comorbidity. Our objective was to describe the…”
Get full text

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients by Sanmamed, M.F., Perez-Gracia, J.L., Schalper, K.A., Fusco, J.P., Gonzalez, A., Rodriguez-Ruiz, M.E., Oñate, C., Perez, G., Alfaro, C., Martín-Algarra, S., Andueza, M.P., Gurpide, A., Morgado, M., Wang, J., Bacchiocchi, A., Halaban, R., Kluger, H., Chen, L., Sznol, M., Melero, I.

“…Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We evaluated changes…”
Get full text